HEMO vs. OBI, ONC, OPTI, SBTX, OBD, NSCI, DEST, SNG, C4XD, and IMM
Should you be buying Hemogenyx Pharmaceuticals stock or one of its competitors? The main competitors of Hemogenyx Pharmaceuticals include Ondine Biomedical (OBI), Oncimmune (ONC), OptiBiotix Health (OPTI), SkinBioTherapeutics (SBTX), Oxford BioDynamics (OBD), NetScientific (NSCI), Destiny Pharma (DEST), Synairgen (SNG), C4X Discovery (C4XD), and ImmuPharma (IMM). These companies are all part of the "biotechnology" industry.
Hemogenyx Pharmaceuticals (LON:HEMO) and Ondine Biomedical (LON:OBI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings.
Hemogenyx Pharmaceuticals has a beta of 3.05, suggesting that its share price is 205% more volatile than the S&P 500. Comparatively, Ondine Biomedical has a beta of -0.01, suggesting that its share price is 101% less volatile than the S&P 500.
Hemogenyx Pharmaceuticals has higher earnings, but lower revenue than Ondine Biomedical. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.
0.8% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.5% of Ondine Biomedical shares are owned by institutional investors. 10.7% of Hemogenyx Pharmaceuticals shares are owned by insiders. Comparatively, 50.0% of Ondine Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Hemogenyx Pharmaceuticals had 1 more articles in the media than Ondine Biomedical. MarketBeat recorded 1 mentions for Hemogenyx Pharmaceuticals and 0 mentions for Ondine Biomedical. Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Ondine Biomedical'saverage media sentiment score.
Hemogenyx Pharmaceuticals received 54 more outperform votes than Ondine Biomedical when rated by MarketBeat users. However, 100.00% of users gave Ondine Biomedical an outperform vote while only 57.89% of users gave Hemogenyx Pharmaceuticals an outperform vote.
Ondine Biomedical's return on equity of -144.07% beat Hemogenyx Pharmaceuticals' return on equity.
Summary
Hemogenyx Pharmaceuticals and Ondine Biomedical tied by winning 6 of the 12 factors compared between the two stocks.
Get Hemogenyx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HEMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hemogenyx Pharmaceuticals Competitors List
Related Companies and Tools
